ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

RSLS ReShape Lifesciences Inc

0.170899
-0.0044 (-2.51%)
Última actualización: 14:41:50
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
ReShape Lifesciences Inc RSLS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0044 -2.51% 0.170899 14:41:50
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.175 0.1676 0.179 0.1753
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/4/202415:05GLOBEReShape Lifesciences® Reports Year Ended December 31, 2023..
28/3/202407:31GLOBEReShape Lifesciences® Receives Notice of Allowance for..
04/3/202407:31GLOBEReShape Lifesciences® Provides Update on 2024 Cost Reduction..
26/2/202415:19EDGAR2Form 8-K - Current report
22/2/202407:31GLOBEReShape Lifesciences® Announces First Surgeries Utilizing..
24/1/202407:31GLOBEReShape Lifesciences® Conducts Bariatric Fellows Training..
18/1/202415:38EDGAR2Form 8-K - Current report
16/1/202417:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/1/202415:14EDGAR2Form PRE 14A - Other preliminary proxy statements
20/12/202307:31GLOBEReShape Lifesciences® Engages Maxim Group LLC To Identify..
12/12/202315:05GLOBEReShape Lifesciences® Receives FDA PMA Supplement Approval..
29/11/202315:05EDGAR2Form 8-K - Current report
21/11/202307:06GLOBEReShape Lifesciences® Enters into Warrant Exercise..
08/11/202315:05GLOBEReShape Lifesciences® Reports Third Quarter Ended September..
06/11/202307:31GLOBEReShape Lifesciences® to Announce Financial Results for the..
13/10/202315:42EDGAR2Form 8-K - Current report
05/10/202315:05EDGAR2Form 8-K - Current report
03/10/202308:23EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
29/9/202311:30GLOBEReShape Lifesciences® Announces Pricing of $3.0 Million..
27/9/202316:30EDGAR2Form S-1/A - General form for registration of securities..
22/9/202315:02EDGAR2Form 8-K - Current report
22/9/202307:31GLOBEReShape Lifesciences® Announces Participation in the LD..
21/9/202307:31GLOBEReShape Lifesciences® Signs Exclusive License Agreement With..
19/9/202307:31GLOBEReShape Lifesciences® Significantly Strengthens Patent..
14/9/202307:31GLOBEReShape Lifesciences® Receives NIH SBIR Grant to Further..
25/8/202315:41EDGAR2Form S-1 - General form for registration of securities under..
07/8/202316:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202315:54EDGAR2Form 8-K - Current report
07/8/202315:05GLOBEReShape Lifesciences® Reports Second Quarter Ended June 30,..
03/8/202315:05GLOBEReShape Lifesciences® to Announce Financial Results for the..
29/6/202307:31GLOBEReShape Lifesciences® Signs Preferred Partner Agreement With..
28/6/202307:31GLOBEReShape Lifesciences® Presents Data on its Proprietary..
26/6/202315:05GLOBEReShape Lifesciences® Submits FDA PMA Supplement Application..
23/6/202307:35GLOBELife Science Investor Forum: Presentations Now Available for..
20/6/202309:58GLOBELife Science Investor Forum Agenda Announced for June 22nd
14/6/202307:31GLOBEReShape Lifesciences® to Participate in Investor and..
15/5/202315:05GLOBEReShape Lifesciences® Reports First Quarter Ended March 31,..
11/5/202307:30GLOBEReShape Lifesciences® to Announce Financial Results for the..

Su Consulta Reciente

Delayed Upgrade Clock